GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Telo Genomics TELO.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

0.05

—

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in CAD, from our data supplier.

FY2025

Net income

−C$2.7m

FY2016FY2025

Free cash flow

−C$2.3m

FY2016FY2025

Shareholders' equity

C$514,981

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit——−C$33,114−C$56,956−C$62,228−C$64,719−C$82,909———
Research and developmentC$1.4mC$1.4mC$1.4mC$1.1mC$603,900C$364,744C$196,774C$1.5mC$1.1mC$502,189
Operating income−C$2.7m−C$2.7m−C$2.8m−C$2.1m−C$1.1m−C$1.2m−C$1.1m−C$4.5m−C$9.3m−C$73,491
Net income−C$2.7m−C$2.7m−C$2.8m−C$2.1m−C$1.1m−C$1.2m−C$1.1m−C$4.7m−C$9.9m−C$70,053
Diluted earnings per share-0.04-0.04-0.04-0.04-0.02-0.03-0.04-0.07-0.17-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$911,300C$965,644C$2.9mC$2.8mC$3.8mC$1.2mC$262,668C$429,515C$3.1mC$601,316
Cash and short-term investments——C$2.7mC$2.7mC$3.6mC$920,983C$19,495C$67,331C$1.2mC$318,542
Total liabilitiesC$396,319C$375,587C$312,869C$230,072C$153,656C$393,419C$1.3mC$743,532C$886,251C$34,869
Debt——C$32,500C$40,000C$40,000C$40,000C$280,000——C$95,330
Shareholders' equityC$514,981C$590,057C$2.6mC$2.6mC$3.7mC$775,254−C$1.0m−C$314,017C$2.2mC$566,447
Shares outstanding71m71m71m59m58m42m24m67m58m48m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$2.3m−C$2.5m−C$2.6m−C$1.8m−C$1.1m−C$1.1m−C$327,836−C$3.2m−C$7.9m−C$78,651
Capital spending−C$3,250−C$5,115−C$69,062−C$25,193−C$9,310−C$8,671−C$9,310−C$23,167−C$477,719−C$144,584
Free cash flow−C$2.3m−C$2.5m−C$2.7m−C$1.8m−C$1.1m−C$1.1m−C$337,146−C$3.2m−C$8.4m−C$223,235

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Operating income−C$575,854−C$526,621−C$541,685−C$690,292−C$845,109−C$614,217−C$552,764−C$599,253
Net income−C$560,478−C$526,621−C$541,685−C$706,663−C$845,109−C$614,217−C$552,764−C$599,253
Diluted earnings per share-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Total assetsC$1.2mC$337,792C$606,896C$911,300C$1.4mC$2.4mC$440,183C$965,644
Shareholders' equity−C$970,209−C$553,325−C$26,704C$514,981C$1.1mC$1.7mC$37,118C$590,057

Growth per year

Compound annual rate

3 years5 years10 years
Operating income8.6%17.3%37.5%
Net income8.8%17.0%38.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-1.3-3.4-5.1-10.0-22.4-9.2-2.6-1.6-3.2-1262.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 22 Nov 2019
  • 2-to-1 reverse split · 30 Aug 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.